No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CSL Carlisle Companies
- 408.850
- +3.390+0.84%
Close Jul 3 13:00 ET
- 409.470
- +0.620+0.15%
Post 15:59 ET
19.46BMarket Cap23.78P/E (TTM)
410.740High402.835Low258.51KVolume405.660Open405.460Pre Close105.62MTurnover0.55%Turnover Ratio26.93P/E (Static)47.60MShares430.21052wk High6.81P/B19.28BFloat Cap233.98952wk Low3.30Dividend TTM47.15MShs Float430.210Historical High0.81%Div YieldTTM1.95%Amplitude8.901Historical Low408.590Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Carlisle Companies' (NYSE:CSL) Investors Will Be Pleased With Their Solid 209% Return Over the Last Five Years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on the bright side, you can make far more than 100% on a really good stoc
Is Now The Time To Look At Buying Carlisle Companies Incorporated (NYSE:CSL)?
Does Carlisle Companies Incorporated (CSL)'s Strong Financial Performance Make It a Good Buy?
North American Spray Foam Insulation Market 2024: Trends, Opportunities and Competitive Analysis 2018-2030 Featuring BASF, FFL Partners, Carlisle Companies, and Huntsman
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today
Carlisle Companies (NYSE:CSL) has outperformed the market over the past 5 years by 11.11% on an annualized basis producing an average annual return of 24.4%. Currently, Carlisle Companies has a market
Honeywell (HON) to Gain From Business Strength Amid Risks
Comments
The share price has tracked EPS growth, suggesting market sentiment towards the shares remains steady. The stock's recent performance has improved, with a better one-year total shareholder return than the five-year return. Dividends have enhanced the total shareholder return.
CSL anticipates robust annualized double-digit earnings growth over the medium term, driven by strong patient demand for its immunoglobulins franchise. The company has bounced back from the pandemic's impact on its blood plasma collections.
The positive trends in Carlisle Companies' ROCE and its ability to consistently reinvest in itself make it an attractive investment. Investors are expecting more growth in the future. However, it's important to check if these trends will continue.
The stock is seen as overpriced by valuation models, making it less attractive for purchase. With the company's low likelihood of significant earnings growth, its investment appeal is diminished. Profits could be made if share prices meet realistic values.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg